Physician profile
Michael B Platt
NPI 1588801500
$11,613.70
in general payments reported to CMS, 2019-2025
23 companies · $4,180 in 2025
The $4,180 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $141 · 2021: $357 · 2022: $740 · 2023: $1,043 · 2024: $4,618 · 2025: $4,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,861 · Consulting Fee: $1,840 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,861.43 |
| Consulting Fee | $1,840.00 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,782.66 | 2024-2025 | Cobenfy |
| Abbvie INC. | $1,803.02 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,214.96 | 2019-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $855.85 | 2020-2025 | Rejoyn, Rexulti |
| Axsome Therapeutics, INC. | $855.39 | 2023-2025 | Auvelity |
| Alkermes, INC. | $810.01 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $518.44 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.44 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $482.74 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Corium, LLC | $437.00 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $341.80 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $257.04 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $143.54 | 2019-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $127.62 | 2020-2025 | Fanapt |
| Livanova USA, INC. | $123.16 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $103.43 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $80.76 | 2019-2024 | Trintellix |
| Allergan, INC. | $52.51 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $43.42 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $25.84 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.51 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $18.08 | 2024 | Quviviq |
| Indivior INC. | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Platt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.